These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10804288)

  • 1. Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers.
    Kashima K; Oite T; Aoki Y; Takakuwa K; Aida H; Nagata H; Sekine M; Wu HJ; Hirai Y; Wada Y; Yamamoto K; Hasegawa K; Sonoda T; Maruo T; Nagata I; Ohno M; Suzuki M; Kobayashi I; Kuzuya K; Takahashi T; Torii Y; Tanaka K
    Jpn J Cancer Res; 2000 Apr; 91(4):399-409. PubMed ID: 10804288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
    Werness BA; Parvatiyar P; Ramus SJ; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; DiCioccio RA; Wiest J; Tsukada Y; Ponder BA; Piver MS
    J Natl Cancer Inst; 2000 Jul; 92(13):1088-91. PubMed ID: 10880552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An antibody assay predictive of BRCA1 mutations in ovarian tumors and normal tissue.
    Byrne TJ; Reece MT; Adams LA; Lane MA; Cohn GM
    Oncol Rep; 2000; 7(5):949-53. PubMed ID: 10948320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of heterozygosity at BRCA1/2 loci in hereditary and sporadic ovarian cancers.
    Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
    J Appl Genet; 2009; 50(4):379-84. PubMed ID: 19875889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased incidence of brain metastases in BRCA1-related ovarian cancers.
    Sekine M; Yoshihara K; Komata D; Haino K; Nishino K; Tanaka K
    J Obstet Gynaecol Res; 2013 Jan; 39(1):292-6. PubMed ID: 22889437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xp22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer.
    Buekers TE; Lallas TA; Buller RE
    Gynecol Oncol; 2000 Mar; 76(3):418-22. PubMed ID: 10684722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
    Merajver SD; Frank TS; Xu J; Pham TM; Calzone KA; Bennett-Baker P; Chamberlain J; Boyd J; Garber JE; Collins FS
    Clin Cancer Res; 1995 May; 1(5):539-44. PubMed ID: 9816013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
    Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
    Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers.
    Russell PA; Pharoah PD; De Foy K; Ramus SJ; Symmonds I; Wilson A; Scott I; Ponder BA; Gayther SA
    Int J Cancer; 2000 Aug; 87(3):317-21. PubMed ID: 10897034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
    Berchuck A; Heron KA; Carney ME; Lancaster JM; Fraser EG; Vinson VL; Deffenbaugh AM; Miron A; Marks JR; Futreal PA; Frank TS
    Clin Cancer Res; 1998 Oct; 4(10):2433-7. PubMed ID: 9796975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
    Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
    Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations.
    Ghimenti C; Sensi E; Presciuttini S; Brunetti IM; Conte P; Bevilacqua G; Caligo MA
    Genes Chromosomes Cancer; 2002 Mar; 33(3):235-42. PubMed ID: 11807980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of BRCA1 dysfunction in ovarian cancer.
    Geisler JP; Hatterman-Zogg MA; Rathe JA; Buller RE
    J Natl Cancer Inst; 2002 Jan; 94(1):61-7. PubMed ID: 11773283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
    Rzepecka IK; Szafron L; Stys A; Bujko M; Plisiecka-Halasa J; Madry R; Osuch B; Markowska J; Bidzinski M; Kupryjanczyk J
    Cancer Genet; 2012 Mar; 205(3):94-100. PubMed ID: 22469508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
    Dimitrova D; Ruscito I; Olek S; Richter R; Hellwag A; Türbachova I; Woopen H; Baron U; Braicu EI; Sehouli J
    Tumour Biol; 2016 Sep; 37(9):12329-12337. PubMed ID: 27297669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
    Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcellular localization and analysis of apparent 180-kDa and 220-kDa proteins of the breast cancer susceptibility gene, BRCA1.
    Thomas JE; Smith M; Rubinfeld B; Gutowski M; Beckmann RP; Polakis P
    J Biol Chem; 1996 Nov; 271(45):28630-5. PubMed ID: 8910495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study.
    Pérez-Vallés A; Martorell-Cebollada M; Nogueira-Vázquez E; García-García JA; Fuster-Diana E
    J Clin Pathol; 2001 Jun; 54(6):476-80. PubMed ID: 11376024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.